Block Listing Application

Vectura Group plc

BLOCK LISTING APPLICATION

Chippenham, UK, 24 September 2015: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces that application has been made to the UK Listing Authority and the London Stock Exchange for a block listing of 5,000,000 ordinary shares of 0.025 pence each.

The application is in respect of shares to be issued pursuant to the exercise of awards under the following Vectura Group Share Option Plans:

The new shares will, when issued, rank pari passu with the existing ordinary share capital of the Company. It is expected that admission will become effective on 25 September 2015.

Enquiries:

Vectura Group plc

 Notes for Editors:

About Vectura

Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth $44 billion worldwide1.

Vectura now has eight products marketed by partners with growing global royalty streams and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura currently has disclosed development collaborations and licence agreements with several global pharmaceutical and biotechnology companies, including Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols, Janssen Biotech and Tianjin KingYork Group Company.

Vectura develops products for airways diseases and owns formulation and inhalation technologies that are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.

For further information, please visit Vectura's website at www.vectura.com.